Browsing Tag

Palisade

Drivers Can Now Buy the New 2023 Hyundai Palisade Calligraphy at Coastal Hyundai

Justine Nov 23, 2022

Customers who want to own the latest 2023 Hyundai Palisade Calligraphy can buy it at the Coastal Hyundai dealership. …

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on…

Jason Junior Sep 15, 2022

CARLSBAD, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that…

Health

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148…

Jason Junior Aug 17, 2022

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first…

Health

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that…

Jason Junior Aug 1, 2022

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its…

Health

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Jason Junior May 13, 2022

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions CARLSBAD, Calif., May 13,…

Health

Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference

Jason Junior Feb 18, 2022

CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom…

Health

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder…

Jason Junior Sep 13, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current…

Health

Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for…

Jason Junior Jul 13, 2021

CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it entered into an…

Health

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide…

Jason Junior Jun 15, 2021

CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its…

Health

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Jason Junior May 7, 2021

CARLSBAD, Calif. and SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial evaluating lead drug candidate LB1148 for…